Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections

Sonia Luque; Nuria Campillo; Francisco Álvarez-Lerma; Olivia Ferrández; Juan Pablo Horcajada; Santiago Grau

doi:10.1016/j.eimc.2015.02.021

Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections

Sonia Luque, Nuria Campillo, Francisco Álvarez-Lerma, Olivia Ferrández, Juan Pablo Horcajada, Santiago Grau

Research output: Contribution to journal › Article › Research › peer-review

8 Citations (Scopus)

Abstract

© 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica In this prospective observational study performed in 12 hospitalized patients with proven or suspected invasive fungal infection treated for a mean of 14 days with micafungin (MCF), 8 of whom with pre-existing liver function impairment, plasma levels of MCF at steady state were not correlated with liver function tests at the beginning of treatment. Liver function remained stable or even improved in all patients, except in one in which MCF was discontinued due to liver toxicity.

Original language	English
Pages (from-to)	652-654
Journal	Enfermedades Infecciosas y Microbiologia Clinica
Volume	34
Issue number	10
DOIs	https://doi.org/10.1016/j.eimc.2015.02.021
Publication status	Published - 1 Dec 2016

Keywords

Hepatotoxicity
Micafungin
Therapeutic drug monitoring

Access to Document

10.1016/j.eimc.2015.02.021

Cite this

@article{9edcf15e96934f38bfca3bb4fa88c235,

title = "Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections",

abstract = "{\textcopyright} 2015 Elsevier Espa{\~n}a, S.L.U. and Sociedad Espa{\~n}ola de Enfermedades Infecciosas y Microbiolog{\'i}a Cl{\'i}nica In this prospective observational study performed in 12 hospitalized patients with proven or suspected invasive fungal infection treated for a mean of 14 days with micafungin (MCF), 8 of whom with pre-existing liver function impairment, plasma levels of MCF at steady state were not correlated with liver function tests at the beginning of treatment. Liver function remained stable or even improved in all patients, except in one in which MCF was discontinued due to liver toxicity.",

keywords = "Hepatotoxicity, Micafungin, Therapeutic drug monitoring",

author = "Sonia Luque and Nuria Campillo and Francisco {\'A}lvarez-Lerma and Olivia Ferr{\'a}ndez and Horcajada, {Juan Pablo} and Santiago Grau",

year = "2016",

month = dec,

day = "1",

doi = "10.1016/j.eimc.2015.02.021",

language = "English",

volume = "34",

pages = "652--654",

journal = "Enfermedades Infecciosas y Microbiologia Clinica",

issn = "0213-005X",

publisher = "Ediciones Doyma, S.L.",

number = "10",

}

Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections. / Luque, Sonia; Campillo, Nuria; Álvarez-Lerma, Francisco et al.

In: Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, No. 10, 01.12.2016, p. 652-654.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections

AU - Luque, Sonia

AU - Campillo, Nuria

AU - Álvarez-Lerma, Francisco

AU - Ferrández, Olivia

AU - Horcajada, Juan Pablo

AU - Grau, Santiago

PY - 2016/12/1

Y1 - 2016/12/1

N2 - © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica In this prospective observational study performed in 12 hospitalized patients with proven or suspected invasive fungal infection treated for a mean of 14 days with micafungin (MCF), 8 of whom with pre-existing liver function impairment, plasma levels of MCF at steady state were not correlated with liver function tests at the beginning of treatment. Liver function remained stable or even improved in all patients, except in one in which MCF was discontinued due to liver toxicity.

AB - © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica In this prospective observational study performed in 12 hospitalized patients with proven or suspected invasive fungal infection treated for a mean of 14 days with micafungin (MCF), 8 of whom with pre-existing liver function impairment, plasma levels of MCF at steady state were not correlated with liver function tests at the beginning of treatment. Liver function remained stable or even improved in all patients, except in one in which MCF was discontinued due to liver toxicity.

KW - Hepatotoxicity

KW - Micafungin

KW - Therapeutic drug monitoring

U2 - 10.1016/j.eimc.2015.02.021

DO - 10.1016/j.eimc.2015.02.021

M3 - Article

SN - 0213-005X

VL - 34

SP - 652

EP - 654

JO - Enfermedades Infecciosas y Microbiologia Clinica

JF - Enfermedades Infecciosas y Microbiologia Clinica

IS - 10

ER -

Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections

Abstract

Keywords

Access to Document

Fingerprint

Cite this